targeting her2, braf, kras, met
Published 8 years ago • 1.6K plays • Length 21:10
Download video MP4
Download video MP3
Similar videos
-
22:50
targeting her2, braf, kras, met, trk
-
14:45
potential and progress in targeting less common markers: her2, braf, kras, met, trk, and ret
-
21:23
her-2/braf/kras and met
-
15:52
debate: are novel targets such as her2 ready for prime time in colorectal cancer? - no
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
22:10
novel agents and targets in colorectal cancer
-
21:36
strategies for overcoming kras mutations
-
22:40
how to approach the patient with braf mutant tumor
-
0:30
dr. infante talks about braf mutation testing
-
24:33
molecular markers beyond kras for anti-egfr targeted agents — what is new?
-
0:52
dr. graff on genomic risk prediction in hr /her2- breast cancer
-
22:49
biomarkers for treatment selection in colon cancer
-
27:28
advances in therapy for braf-mutant melanoma
-
47:45
resistance in braf and kras mutant cancers - by ryan corcoran, md, phd
-
26:57
segment 2: molecular targets in nsclc
-
2:34
characterizing and targeting class ii/iii braf alterations
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
13:59
debate 2: braf mutant mcrc patients - clinical trial
Clip.africa.com - Privacy-policy